Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment

Gerhard Zugmaier, Nicola Gökbuget, Matthias Klinger, Andreas Viardot, Matthias Stelljes, Svenja Neumann, Heinz-A. Horst, Reinhard Marks, Christoph Faul, Helmut Diedrich, Albrecht Reichle, Monika Brüggemann, Chris Holland, Margit Schmidt, Hermann Einsele, Ralf C. Bargou, Max S. Topp

Blood (2015) 126 (24): 2578–2584.

https://doi.org/10.1182/blood-2015-06-649111

Published: 2015

Includes: Supplemental data

Journal Articles

Long-Term Survival in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) Who Achieved Minimal Residual Disease (MRD) Response Following Anti-CD19 BiTE ® Blinatumomab

Gerhard Zugmaier, Nicola Goekbuget, Andreas Viardot, Matthias Stelljes, Svenja Neumann, Heinz A. Horst, Albrecht Reichle, Reinhard Marks, Christoph Faul, Monika Brueggemann, Chris Holland, Margit Schmidt, Noemi Mergen, Marie-Elisabeth Goebeler, Hermann Einsele, Ralf C. Bargou, Max S. Topp

Blood (2014) 124 (21): 2287.

https://doi.org/10.1182/blood.V124.21.2287.2287

Published: 2014

Journal Articles

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

Blood (2012) 120 (26): 5185–5187.

https://doi.org/10.1182/blood-2012-07-441030

Published: 2012

Journal Articles

Blinatumomab Monotherapy Shows Efficacy in Patients with Relapsed Diffuse Large B Cell Lymphoma

Blood (2011) 118 (21): 1637.

https://doi.org/10.1182/blood.V118.21.1637.1637

Published: 2011

Journal Articles

CD19/CD3 Bispecific Antibody Blinatumomab (MT-103) Is Highly Effective In Treatment of Patients with Minimal Residual Disease From Chemotherapy-Resistant B-Precursor Acute Lymphoblastic Leukemia

Blood (2010) 116 (21): 174.

https://doi.org/10.1182/blood.V116.21.174.174

Published: 2010

Journal Articles

Treatment of Patients with Non-Hodgkin Lymphoma (NHL) with CD19/CD3 Bispecific Antibody Blinatumomab (MT103): Double-Step Dose Increase to Continuous Infusion of 60 μg/m 2 /d Is Tolerable and Highly Effective

Andreas Viardot, MD, Mariele Goebeler, MD, Jurgen S. Scheele, MD, PhD, Gerhard Zugmaier, MD, Richard Noppeney, MD, Stefan Knop, MD, Max S Topp, MD, Dirk Nagorsen, MD, Matthias Klinger, PhD, Margit Schmidt, PhD, Petra Klappers, Peter Kufer, MD, Hermann Einsele, MD, Ralf Bargou, MD

Blood (2010) 116 (21): 2880.

https://doi.org/10.1182/blood.V116.21.2880.2880

Published: 2010

Journal Articles

Transient Laboratory Findings Upon First Dosing with T-Cell Engaging BiTE® Antibody Blinatumomab in Non-Hodgkin Lymphoma Patients.

Dirk Nagorsen, Gerhard Zugmaier, Peter Kufer, Matthias Klinger, Andreas Viardot, Mariele Goebeler, Margit Schmidt, Petra Klappers, Andreas Wolf, Christian Brandl, Patrick A Baeuerle, Ralf C Bargou

Blood (2009) 114 (22): 4798.

https://doi.org/10.1182/blood.V114.22.4798.4798

Published: 2009

Journal Articles

Report of a Phase II Trial of Single-Agent BiTE® Antibody Blinatumomab in Patients with Minimal Residual Disease (MRD) Positive B-Precursor Acute Lymphoblastic Leukemia (ALL).

Blood (2009) 114 (22): 840.

https://doi.org/10.1182/blood.V114.22.840.840

Published: 2009

Journal Articles

Confirmation of Safety, Efficacy and Response Duration in Non-Hodgkin Lymphoma Patients Treated with 60 μg/m 2 /d of BiTE® Antibody Blinatumomab.

Dirk Nagorsen, Gerhard Zugmaier, Andreas Viardot, Mariele Goebeler, Richard Noppeney, Margit Schmidt, Petra Klappers, Patrick A Baeuerle, Peter Kufer, Ralf C Bargou

Blood (2009) 114 (22): 2723.

https://doi.org/10.1182/blood.V114.22.2723.2723

Published: 2009

Journal Articles

Sustained Response Duration Seen after Treatment with Single Agent Blinatumomab (MT103/MEDI-538) in the Ongoing Phase I Study MT103- 104 in Patients with Relapsed NHL

Ralf C Bargou, MD, Peter Kufer, MD, Mariele Goebeler, MD, Stefan Knop, MD, Hermann Einsele, MD, Richard Noppeney, MD, Andreas Viardot, MD, Patrick A Baeuerle, PhD, Carsten Reinhardt, MD, Margit Schmidt, PhD, Petra Klappers, Dirk Nagorsen, MD, Gerhard Zugmaier, MD

Blood (2008) 112 (11): 267.

https://doi.org/10.1182/blood.V112.11.267.267

Published: 2008

Journal Articles

Treatment with Anti-CD19 BiTE Antibody Blinatumomab (MT103 / MEDI-538) Is Able to Eliminate Minimal Residual Disease (MRD) in Patients with B-Precursor Acute Lymphoblastic Leukemia (ALL): First Results of An Ongoing Phase II Study.

Max Topp, MD, Nikola Goekbuget, MD, Peter Kufer, MD, Gerhard Zugmaier, MD, Evelyn Degenhard, Svenja Neumann, MD, Heinz A Horst, MD, Andreas Viardot, MD, Mathias Schmid, MD, Oliver G. Ottmann, MD, Margit Schmidt, PhD, Carsten Reinhardt, MD, Patrick A Baeuerle, PhD, Dirk Nagorsen, MD, Dieter Hoelzer, MD, PhD, Ralf C. Bargou, MD

Blood (2008) 112 (11): 1926.

https://doi.org/10.1182/blood.V112.11.1926.1926

Published: 2008

NARROW

Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment

Long-Term Survival in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) Who Achieved Minimal Residual Disease (MRD) Response Following Anti-CD19 BiTE ® Blinatumomab

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

Blinatumomab Monotherapy Shows Efficacy in Patients with Relapsed Diffuse Large B Cell Lymphoma

CD19/CD3 Bispecific Antibody Blinatumomab (MT-103) Is Highly Effective In Treatment of Patients with Minimal Residual Disease From Chemotherapy-Resistant B-Precursor Acute Lymphoblastic Leukemia

Treatment of Patients with Non-Hodgkin Lymphoma (NHL) with CD19/CD3 Bispecific Antibody Blinatumomab (MT103): Double-Step Dose Increase to Continuous Infusion of 60 μg/m 2 /d Is Tolerable and Highly Effective

Transient Laboratory Findings Upon First Dosing with T-Cell Engaging BiTE® Antibody Blinatumomab in Non-Hodgkin Lymphoma Patients.

Report of a Phase II Trial of Single-Agent BiTE® Antibody Blinatumomab in Patients with Minimal Residual Disease (MRD) Positive B-Precursor Acute Lymphoblastic Leukemia (ALL).

Confirmation of Safety, Efficacy and Response Duration in Non-Hodgkin Lymphoma Patients Treated with 60 μg/m 2 /d of BiTE® Antibody Blinatumomab.

Sustained Response Duration Seen after Treatment with Single Agent Blinatumomab (MT103/MEDI-538) in the Ongoing Phase I Study MT103- 104 in Patients with Relapsed NHL

Treatment with Anti-CD19 BiTE Antibody Blinatumomab (MT103 / MEDI-538) Is Able to Eliminate Minimal Residual Disease (MRD) in Patients with B-Precursor Acute Lymphoblastic Leukemia (ALL): First Results of An Ongoing Phase II Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only